tradingkey.logo
tradingkey.logo
Search

Supernus Pharmaceuticals Inc

SUPN
Add to Watchlist
44.380USD
+0.800+1.84%
Close 06/18, 16:00ETQuotes delayed by 15 min
2.53BMarket Cap
LossP/E TTM

Earnings Forecast

Currency: USD Updated: 2026-06-18
Previous score
8.33
Change
0
The current earnings forecast score of Supernus Pharmaceuticals Inc is 8.33, ranking 40 out of 157 in the Pharmaceuticals industry. The average price target is 61.50, with a high of 65.00 and a low of 50.00.

Analyst Rating

Based on 6 analysts
Buy
Current Rating
62.833
Target Price
+44.18%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Supernus Pharmaceuticals Inc
SUPN
6
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Forecast
Actual

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

FAQs

What is Supernus Pharmaceuticals Inc's expected revenue for the next quarter?

Supernus Pharmaceuticals Inc's expected revenue is 205.29M.

What is Supernus Pharmaceuticals Inc's price target?

Analysts forecast that Supernus Pharmaceuticals Inc's price target is USD 61.50, with the highest forecast at USD 65.00 and the lowest forecast at USD 50.00.

How have Supernus Pharmaceuticals IncSUPN's recent earnings per share performed?

The market expectation was USD -0.04, while Supernus Pharmaceuticals IncSUPN's earnings per share (EPS) for the previous quarter was USD -0.07. EPS for the next quarter is expected at USD 0.43.

What is the analyst rating for Supernus Pharmaceuticals Inc?

Based on the ratings of Supernus Pharmaceuticals Inc's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
KeyAI